Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06407973 · ClinicalTrials.gov registry record · Phase 4
A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma
A Phase 4 study, sponsored by Sight Sciences.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT06407973: Clinical Trial Phase 4 study, sponsored by Sight Sciences.
NCT06407973 is a Phase 4 study that was terminated before completion, run by Sight Sciences. The registered enrollment target is 2 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06407973, a Phase 4 study, was terminated before completion, sponsored by Sight Sciences.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
A Randomized Clinical Trial of Ab Interno Canaloplasty and Trabeculotomy with the OMNI® Surgical System Compared to Standard Medical Treatment as a Standalone Procedure in Patients with Primary Open Angle Glaucoma (EVOLVE)
Primary Outcome
Proportion of subjects with a ≥ 20% reduction from medicated baseline in mean diurnal IOP (DIOP) at 12 months post-operatively
Interventions
- DEVICE OMNI Surgical System
- DRUG Latanoprost plus adjunctive glaucoma medication
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2024-08-21 |
| Est. Completion | 2025-01-20 |
| Phase | Phase 4 |
Why NCT06407973 stopped before completion
NCT06407973 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which OMNI Surgical System is the first listed.
NCT06407973 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06407973 about?
NCT06407973 is a clinical study titled "A Clinical Trial Comparing the OMNI Surgical System to Standard Medical Treatment in Patients With Primary Open Angle Glaucoma". A Randomized Clinical Trial of Ab Interno Canaloplasty and Trabeculotomy with the OMNI® Surgical System Compared to Standard Medical Treatment as a Standalone Procedure in Patients with Primary Open Angle Glaucoma (EVOLVE)
What is the current status of trial NCT06407973?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2024-08-21. Estimated completion is 2025-01-20.
What interventions are being tested in trial NCT06407973?
The interventions under investigation include: OMNI Surgical System (DEVICE), Latanoprost plus adjunctive glaucoma medication (DRUG).
Who is sponsoring clinical trial NCT06407973?
This trial is sponsored by Sight Sciences, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06407973's enrollment target sits among peer trials
2 1998th of 2000 higher than 1 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI